NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Tirzepatide from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
+8 more ↓
77%
Finnrick rating
#151 of 281 Tirzepatide vendors
49 of 65 classifiable tests passed
customers 4.3★ (48)
methodology · Purity focus
Finnrick analysis · Tirzepatide

Repeated sub-99.5% purity results keep this profile mixed, with notable fill outliers including +59% and +78% overfills. Later tests trend cleaner, but the Aug–Sep purity misses show the improvement is not fully steady.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Nexaph's public pages point to Shanghai Nexa Pharma Co, Nevis terms, and an Indiana operating footprint without resolving the legal counterparty. The report maps shared COA infrastructure, sister-brand trails, crypto rails, and a documented batch-sterility thread.

39 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
89%
12
2
Tirzepatideselected
$1.13
77%
65
3
KLOW
$5.72
77%
3
4
Retatrutide
$2.46
76%
108
5
PT-141
-
72%
3
6
BPC-157
$1.51
64%
21
7
Ipamorelin
$1.30
60%
10
8
Cagrilintide
$3.50
51%
13
9
CJC-IPA
$3.96
45%
1
10
Tesamorelin
$2.88
37%
30
11
TB-500
$1.61
37%
7
12
Sermorelin
-
36%
3
13
CJC-1295
$3.40
35%
9
14
Semaglutide
$1.90
35%
15
15
MOTS-c
$1.88
29%
6
16
NAD+
$0.04
28%
3
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%2 Jul 2025: 61%2 Jul 2025: 58%3 Jul 2025: 54%16 Jul 2025: 56%17 Jul 2025: 59%3 Aug 2025: 57%3 Aug 2025: 54%3 Aug 2025: 51%5 Aug 2025: 53%5 Aug 2025: 50%5 Aug 2025: 52%5 Aug 2025: 49%6 Aug 2025: 51%7 Aug 2025: 48%11 Aug 2025: 51%31 Aug 2025: 53%1 Sep 2025: 51%4 Sep 2025: 53%18 Sep 2025: 56%6 Oct 2025: 58%17 Oct 2025: 59%17 Oct 2025: 61%17 Oct 2025: 62%24 Oct 2025: 63%30 Oct 2025: 61%18 Nov 2025: 62%13 Dec 2025: 64%18 Dec 2025: 65%29 Dec 2025: 66%15 Jan 2026: 67%19 Jan 2026: 65%19 Jan 2026: 66%11 Feb 2026: 67%11 Feb 2026: 68%11 Feb 2026: 69%11 Feb 2026: 70%13 Feb 2026: 70%18 Feb 2026: 68%20 Feb 2026: 69%25 Feb 2026: 70%2 Mar 2026: 71%3 Mar 2026: 71%4 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 71%6 Mar 2026: 72%25 Mar 2026: 72%28 Apr 2026: 73%6 May 2026: 74%11 May 2026: 74%12 Jun 2026: 75%15 Jun 2026: 75%15 Jun 2026: 76%26 Jun 2026: 76%21 Jul 2026: 77%4 Aug 2026: 77%9 Aug 2026: 78%27 Aug 2026: 76%10 Sep 2026: 77%10 Sep 2026: 77%20 Sep 2026: 76%24 Sep 2026: 76%13 Oct 2026: 76%23 Oct 2026: 77%2 Nov 2026: 77%15 Nov 2026: current 77%61%66%77%Jul 25Nov 26
Showing Tirzepatide tests only
Peptide testing

Ordered Tirzepatide from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
Nexaph Tirzepatide test history
COA-backed lab tests
1-10 of 65

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 16 peptides and 309 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are BPC-157 (21 tests) and Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Peptide testing

Ordered Tirzepatide from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply